As targeted therapies have become the standard of care in chronic lymphocytic leukemia (CLL), it is increasingly important to refine therapy selection based on risk stratification. An in-depth analysis of community-based CLL practice patterns, registry data, and clinical guidelines can provide a benchmark for your own practice. Does your practice align with current evidence? Hear from expert clinicians, Dr. Matthew Davids and Dr. Nicole Lamanna, as they explore current data and the patient and care-team factors that influence selection of therapy for CLL in the community setting. The panel will provide practical strategies to apply in your practice; which may can include improving timely testing, documentation, risk-stratification, treatment selection, and CLL management. Walk away with ready-to-implement actions to improve your team s management of newly diagnosed and relapsed/refractory CLL.
- Provider:Global Education Group, Ltd.
- Activity Link: http://www.omedlive.com
- Start Date: 2025-01-15 06:00:00
- End Date: 2025-01-15 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.5 hours
- MOC Credit Details: ABIM - 0.5 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: AstraZeneca (Any division) - Amount: 0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Competence, Learner Knowledge
- Provider Ship: Jointly Provided
- Registration: Open to all
- Specialty: Internal Medicine